ArticleBMC infectious diseases2026
Liver function impairment and associated factors among adult human immunodeficency virus infected individuals on antiretroviral therapy at Hosanna town, Central Ethiopia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiretroviral therapy significantly reduces human immunodeficiency virus-related morbidity and mortality. However, this therapy, along with other factors, can cause liver damage. There is a dearth of evidence on liver function impairment among human immunodeficiency virus patients receiving antiretroviral therapy in central Ethiopia. This study aimed to assess the prevalence and factors associated with liver function impairment in adult patients infected with human immunodeficiency virus.
methodsA cross-sectional study among 307 human immunodeficiency virus-positive adults receiving antiretroviral therapy was conducted from December 10, 2023, to March 15, 2024, at Wachamo University Nigist Eleni Mohammed Memorial Comprehensive Specialized Hospital, Ethiopia. The antiretroviral therapy clinic attendants were recruited consecutively, a structured questionnaire was used to collect sociodemographic data, and additional clinical data were collected from medical records. Blood samples were collected, and liver function analytes were determined via a Cobas C311 chemistry analyzer. Hepatitis B and C viruses were tested via a serological test strip. Logistic regression analysis was performed to identify factors associated with liver function impairment via SPSS Version 27.0. P values < 0.05 with a 95% confidence level were considered statistically significant.
resultsAmong the 307 Human immunodeficiency virus patients receiving antiretroviral therapy, 19.2% (95% CI = 15.0-24.1%) had abnormal liver function. All the impairments were Grade I. HBsAg positivity (AOR = 4.03; 95% CI = 1.1-14.8, P = 0.036), the use of herbal medicine (AOR = 4.46; 95% CI = 1.18-16.9, P = 0.028), and the use of anti-tuberculosis drugs (AOR = 3.6; 95% CI = 1.003-13.01, p = 0.05) were factors associated with liver function impairments.
conclusionAccording to this study, liver function impairment was common among individuals living with human immunodeficiency virus and was significantly associated with hepatitis B virus coinfection, herbal medicine use and the use of anti-tuberculosis drugs. Therefore, ART treated patients with these factors require close monitoring before severe adverse consequences occur. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.